Idiopathic epiretinal membrane, macular hole Idiopathic epiretinal membrane, macular hole
Conditions
Interventions
One drop of Brimonidine/Brinzolamide fixed combination ophthalmic suspension is instilled twice-daily for 8 days (7 days before surgery and the operation day in the morning and at 2h before surgery).
Sponsors
Inatani Masaru
Senju Pharmaceutical Co.,Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with written informed consent obtained after adequate explanation on participating the study 2)Male or female,20 years of age or older 3)Patients who undergo vitrectomy for idiopathic epiretinal membrane or macular hole
Exclusion criteria
Exclusion criteria: 1)Patients with ocular inflammation 2)Patients with vitreous hemorrhage 3)Patients with proliferative diabetic retinopathy 4)Patients with severe corneal epithelium disorder 5)Patients with contraindications or patients in whom precautions are required for the use of Brimonidine/ Brinzolamide fixed combination. 6)Patients with a history of serious side effects against alpha 2-adrenergic receptor agonist or carbonic anhydrase inhibitor 7)Women who are pregnant, lactating or may be pregnant, or planning to be pregnant during the study period, or can not agree to contraception 8)Patients who have been considered inappropriate as study subjects by doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of brimonidine in the aqueous humor and vitreous | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of brinzolamide in the aqueous humor and vitreous, Correlation between concentration of drugs in the aqueous humor and vitreous and patient background , ocular fundus (blood vessel), adverse events, visual acuity, intraocular pressure, ophthalmologic findings (cornea, conjunctiva) | — |
Contacts
Public ContactMasaru Inatani
University of Fukui Hospital
Outcome results
None listed